Previous efforts to circumvent the problem of the size limitation imposed by the AAV vector have focused mainly on altering the candidate genes into ‘mini-expression cassettes’ suitable for ...

A new, streamlined AAV purification process that is both universal and scalable could ease commercialization constraint.

AMSBIO announce a new range of ready-to-use adeno-associated virus (AAV) biosensor products. These viruses encode your chosen biosensor, either calcium or glutamate sensor and are ready for in vivo ...

In this valuable manuscript, authors ablate cerebellar oligodendrocytes during postnatal development and show that synchrony of calcium transients in Purkinje neurons and behaviours are affected even ...

AAV vectors are used clinically to treat a number of rare inherited retina diseases, but also carry the risk of eliciting sight threatening ocular inflammation. Establishing how AAV-mediated ...

Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at treating neurological diseases. Astellas will ...

Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...

New Vericheck ddPCR Empty-Full Capsid Kits for AAV Serotypes 2 and 8 Provide Precise Measurement of Viral Titer and Capsid ...

The study presents a potential alternative to adeno-associated virus (AAV)-mediated gene therapy, addressing the exclusion of patients with preexisting anti-AAV antibodies. Severe hemophilia A is ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an ...

Researchers are making strides in improving gene therapies for genetic diseases, particularly chronic kidney disease, using adeno-associated virus, or AAV, vectors. While AAV-based treatments have ...